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ABSTRACT
Advances in Mass-spectrometry techniques allow for the rapid processing and evaluation of complex 
biological mixtures such as blood/serum. These samples represent a protein rich environment as well 
as a sentinel monitoring system of the entire organism. The central tenet of these studies is that 
changes in the microenvironment of a tissue, brought about by a disease process, will lead to 
sufficient changes in the protein and peptide pattern of the serum, such that the differences can be 
accurately detected and correctly associated with a particular disease state.  Using mass-
spectrometry approaches we have developed techniques that allow us to compare samples from 
tumor-free and tumor present serum samples simultaneously to find biomarkers that indicate the 
presence of cancer. To examine potentially important but less abundant proteins, ultrafiltration (UF) 
was used to eliminate the more abundant proteins and combine this with the non-isotopic peptide tags 
(S-methylthioacetimidate and S-methyl thiopropionimidate) described by Beardsley and Reilley (J. 
Proteome Res. 2: 15-21, 2003) to differentiate our samples. Use of these mass-coded abundance tags 
(MCAT) allows for simultaneous evaluation of serum samples from tumor present, and tumor free 
animals. Using an oa time-of-flight mass-spectrometer (Q-tof) with electrospray ionization we produce 
high quality spectrums to screen for peptides that have only one tag. Specificity of tagging increases 
the likelihood that the peptide resulted from a protein unique to either the control or conditioned state. 
Using the ms/ms function of the Q-tof we sequence the peptide and identify the parent protein. 
Specifically, our lab is using UF, MCAT and the Q-tof to evaluate rat models of chemically-induced 
tumors. By using animal models we overcome much of the variability that may exist in human serum 
samples due to differences in gender, diet and cancer initiation. We have shown that these systems 
allow for the identification of both small molecules such as Alpha S1 casein precursor (24 kDa) as well 
as proteins greater than the MCO such as Fibrinogen alpha/alpha E precursor and Coagulation factor 
2 (86 and 70 kDa, respectively). With positive sequence identification we can now evaluate the tumors 
themselves to determine if the proteins are over-expressed in the tumor vs. normal tissues. Using this 
method of “ bottom-up”  analysis provides information on the nature and composition of our samples 
to more rapidly identify those proteins that are unique to the tumor state of the animals.
INTRODUCTION
Serum represents a rich repository of information about the body in terms of biomarkers and 
a readily accessible fluid for collection. The difficulty of using serum for biomarker analysis 
lies in the high abundance of relatively few proteins. Anderson has published that 99% of the 
protein concentration in serum is derived from 22 proteins1 (Figure 1). These proteins cover a 
large dynamic range. Therefore, in order to screen the serum for unique proteins related to a 
developing biological alteration (such as tumor growth) we must have mechanisms to enrich 
for the low abundance proteins, quickly associate their presence with the disease state, and 
identify them to determine their role in the disease process.
To date, the majority of serum studies to date have used human samples. The reasons are 
that these samples are characterized (type and stage of cancer as well as information about 
the patient) and relatively large data sets can be acquired. The underlying problem with these 
projects is the inherent complexity introduced by looking at human populations. Therefore, 
the development of analytical technologies is confounded by having to evaluate both the 
inherent complexity of the analyte and the extrinsic factors associated with clinical samples.
Our goal is to create a system that reduces the complexity of the analyte. We are 
accomplishing this in two ways 1) using a rat model, we can control the day to day variances 
of diet, light cycle, temperature etc., as well knowing the cause of the tumorogenesis and the 
date of induction, and 2) simplify the analyte by eliminating most of the high abundant 
proteins using ultrafiltration (UF). For this, we are applying some of the fractionation 
procedures used in MUD-PIT studies (i.e tryptic digestion and multi-phasic HPLC). The result 
is a sample that is a mixture of all the peptides produced by both endogenous cleavage events 
as well as the in vitro tryptic fragmentation, but will lack an abundance of peptides from the 
most prevalent proteins in the serum. 
The resulting tryptic fragmentation pattern (an N-terminus and a C-terminus with either a 
lysine group or an arginine group) is then used to enhance the analysis by treating the sample 
with one of the two MCAT reagents (S-methylthioacetimidate (S-MTA): +41Da or S-methyl 
thiopropionimidate (S-MTP): +55Da)2. These reagents undergo amindination reactions with all 
lysine residues and the N-terminus. Therefore, each condition receives one tag (e.g. tumor 
samples are tagged with S-MTA and control are tagged with S-MTP). Hence, we can then 
evaluate both the tumor and tumor-free serum simultaneously. Particularly, for MALDI-TOF 
analysis this allows us to overcome several of the variables involved with comparisons of 
different spots.
We propose that by using a controlled environment as well as micro-scale fractionation 
procedures we can readily apply the use of mass-coded abundance tags (MCAT’ s) coupled 
with mass-spectrometry to rapidly assess biomarkers and discover circulating proteins that 
indicate the presence of tumors. 
METHODS AND MATERIALS:
Female Sprague Dawley rats were treated with NMU (50 mg/kg BW) at 50 days of age then 
palpated twice a week to monitor tumor development. After tumors had developed the 
animals were killed, whole trunk blood was collected and serum was separated and stored at 
-80C. Serum samples were then treated similarly to the protocol described by Radhakrishna 
et al3 (Figure 2). Briefly, samples were processed by ultrafiltration using a 30 kDA molecular 
weigh cut-off. The collected fractions were then denatured, reduced and alkylated prior to 
digestion with trypsin. Following digestion samples were checked on the MALDI-TOF to 
ensure complete digestion and evaluate sample recovery (Figure 3). 
Micro-column construction
Each sample required its own micro-column (Figure 4) to ensure that there were no carry-over 
peptides between samples. Each column consisted of fused silica capillary of approximately 
11 cm (180 um i.d.) attached via a PEEK sleeve to a 4 cm piece of fused silica (250 um i.d.). The 
11 cm sections were packed with Jupiter RP material to a length of 1 cm. The second section 
consisted of 2 cm of PolyA (SCX) and the third section was packed with 2 cm of Jupiter RP 
beads.
HPLC
Using a Waters 660E pump and switching system the following conditions were used to for 
peptide separation. All fractions were collected into cells of a 96 well plate with conical bottom 
to ensure greater peptide recovery.
Fraction segments were:
1) 100% ACN
2)   25% KCL followed by 100% ACN
3)   50% KCL followed by 100% ACN
4)   75% KCL followed by 100% ACN
5) 100% KCL followed by 100% ACN
After collected fractions were lyophilized, they were rehydrated in a solution containing 
either SMTA or SMTP (Figure 6) and allowed to sit at room temperature overnight to allow 
complete tagging. Tagged samples were then lyophilized and resuspended in 0.5% FA and 
applied to a 96 well Montage plate (C18 Zip Plate, Millipore). Samples were eluted from the 
plate and collected in a 96 well plate and once again lyophilized. Then these samples are ready 
for mass-spectrometry.
MALDI-TOF
Using a Voyager Elite the samples were analyzed as described by Beardsley & Reilly2. Briefly, 
samples were resuspended in 1% FA and mixed 1:1 with DHB matrix. Each spotted sample 
consisted of 1 ul of S-MTA and 1 ul S-MTP labeled fractions. Using the peptide reflector in the 
positive mode, 100 shots per sample were collected.
Analysis
Spectrums from each collected spot were exported to Excel (Table 1). These excel sheets were 
then imported into SAS. Presently,  we are designing a search algorithm to bin all peaks + or – 
1da, then to search for differences in peak of  +14, +28, +42, +55, +85 and +110 daltons to locate 
peaks of interest, including those that are similar to each other.
90% of serum protein concentration is made by 10 proteins
9% is made of  12 proteins
1% is made of all other proteins and peptides.
Figure 1. This chart shows the 22 most abundant proteins found in serum. 
Taken together they make up 99% of the serum protein concentration.
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Figure 2.Workflow of  the sample preparation steps as described by Radhakrishna 
et al. Ultrafiltration of the serum reduces the complexity of the sample by removing 
predominant proteins, primarily albumin. Tryptic fragmentation allows for MCAT 
additions and the fragment sequence information can be used for protein 
identification.
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Control 1
Tumor 1 Tumor 2
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Figure 3. These MALDI-TOF spectra illustrate the need for separation methods prior to mass 
spectrometry. For the various sample types there are a finite number of peaks that can be 
visualized at any time. To increase the number of peaks available for evaluation we are 
developing HPLC fraction methods.
MALDI-TOF spectrum of UF samples from control and tumor serum before HPLC and tagging
Micro-scale tri-phasic column for serum peptide separation
Figure 4. This is a schematic of the micro-scale HPLC columns constructed 
for peptide separation. The nature of the column allows us to use the 
inherent chemistry of the peptides to get better separation and reduce 
handling, therefore, our overall recovery should improve.
96 well plate with 
conical wellsPoly  A (SCX)Jupiter C-18 Jupiter C-18 Teflon
HPLC
1) S-methylthioacetimidate (S-MTA): +41Da;       2) S-methyl thiopropionimidate (S-MTP): +55Da
•Peptides produced from tryptic digestion are tagged with one of two reagent    tags.
•Each tag will attach to all lysine amino acids or to any free N-terminus
•QUEST (Quantitation Using Enhanced Signal Tags) allows peptides from different 
sample treatments or conditions to be evaluated simultaneously.
•Simultaneous evaluation allows for rapid identification of unique peptides.
Mass-coded Abundance Tags (MCAT)
Each fraction from the HPLC run is collected into one well. After 
collection the samples are spun to dryness. Then the fractions are 
resuspended in a Trizma buffer containing one of the MCAT 
reagents
The samples are again dried and 
then resuspended in formic acid.  Resuspended samples are put into their own wells of a Montage plate (C18 Zip plate) for 
concentration of peptides and salt removal.
The “ clean”  fractions are dried and 
resuspended in formic acid and can now 
be used for MALDI-TOF or other mass-
spectrometry.
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Post-HPLC processing for MCAT addition and preparation for mass-spectrometry
Figure 6. Outline of the treatment of the samples after they have been fractionated by 
HPLC. These steps add the MCAT reagents as well as prepare the samples for mass-
spectrometry.
MALDI-TOF spectrum of tagged peptides from serum
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Figure  7. Appearance of  MALDI-TOF spectrum during a run. The dual sample spectrum is the 
result of a spot containing samples of each tag. Arrows indicate peaks that are the same 
peptide in each sample, but vary by mass due to the tag addition.
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Table 1.  Peaks generated from samples tagged with either S-MTA or S-MTP. Calculations are 
made to look for specific mass differences between peaks based on multiples of the mass 
difference of the tags as well as to look for missed tags. Peak matching allows for rapid 
localization of peaks unique to one of the conditions. Peaks are color coded and three of the 
theoretical additions to the peptides are shown. A shift of 14 Da indicates that the peptide only 
had one molecule of each tag added and a shift of 28 Da would indicate that two of the molecules 
were added to the peptide.
Peak list from individual samples.
FPNAEFAEITK 
Peptide Parent Protein 
FPNAEFAEITK Rat Albumin
IMSMIDEAK Apolipoprotein A-1 precursor
ATIDQNLEDLR Apolipoprotein A-IV precursor
LGPLVEQGR Apolipoprotein E precursor
AFSPVASVESASGEVLHSPK Rat Fetuin precursor
LTAQPAPSPEDLALSMGTIK Alpha I inhibitor III precursor
Table 1. Peptides produced from whole serum digested with trypsin and incubated with S-
methylthiacetimidate. Red letters indicate the sites of tag addition. Tags add only on the N-
terminus and on all Lysine residues (K). Peptides were then sequenced using a Q-ToF mass 
spectrometer (Micromass). The N-terminus labeling is non-amino acid specific. However, the 
labeling will not add to the C-terminus when Arginine (R) is present as a result of the tryptic 
digestion.
From Ultrafiltration trial (this sample was not modified)
Peptide Parent Protein
ADTGTTSEFIEAGGDI Fibrinogen alpha/alpha E precursor*
YQNFDPEVKLV Coagulation factor 2 Rat*
FFVAPFPEVEGK Alpha S1 casein precursor bovine**
YLGYLEQLLR Alpha S1 casein precursor bovine**
*The average mass of these intact proteins is 86Kda and 70Kda, respectively. This demonstrates 
that we can detect the presence of proteins outside the MW cut-off of the ultrafiltration 
probe.**The average mass of this intact protein is 24Kda. This demonstrates that proteins of the 
appropriate MW may enter the probe.
Figure 8. Unique MALDI-TOF peaks can be evaluated by CID ms/ms to provide information on 
the amino acid sequence of the peptide as well as detect the number of sites of tag addition. 
The peptide sequence is then used to get protein identification as shown in the lists on the 
right.
MS/MS spectrum from a Micromass Q-tof.
 DISCUSSION
Advances in mass spectrometry are allowing the evaluation of more complex samples. Therefore, several labs 
have undertaken the goal of screening serum for biomarkers of disease states/processes. Current literature 
points to the fact that only about 1500 proteins have been identified in serum by different technologies. This 
seemingly small number demonstrates the need for improved separation technologies in order to ensure that the 
broadest number of proteins is studied.
Many studies (including our initial attempts here) have focused on looking at presence/absence of proteins for an 
indication of biological significance, purposefully avoiding quantitative analysis. This avoidance may, impart, be 
due to mass spectrometry not being used accurately for quantitation. However, advances such as the 
development of MCAT reagents should allow for this type of analysis to be done reliably. 
Finally, it is important to remember that the data provided by these experiments is a direct reflection of the study 
design. Therefore, high dimensional project development will be open to several sources of variation specifically 
because the instrumentation is so sensitive. So, we suggest that the developmental projects should be 
conducted on more rigorously controlled samples (i.e. animal models) until the technical variability can be 
established and corrected or modeled.
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